Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

10.99 -1.54 (-12.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about NovoCure Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025 ↗
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs. 
Via Benzinga
Topics World Trade
News headline image
NovoCure Surpasses Q1 Expectations ↗
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 24, 2025 ↗
 
Via Benzinga
News headline image
NovoCure's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Why NovoCure Stock Was Withering on Wednesday ↗
Via The Motley Fool
News headline image
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why ↗
Via The Motley Fool
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
NovoCure (NVCR) Q4 2024 Earnings Call Transcript ↗
NVCR earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025 ↗
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion. 
Via Benzinga
News headline image
NovoCure Q4 EPS Misses, Revenue Matches ↗
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges. 
Via The Motley Fool
News headline image
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business' ↗
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business." 
Via Benzinga
News headline image
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? ↗
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
News headline image
Why NovoCure Stock Was Winning Big This Week ↗
Via The Motley Fool
News headline image
Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds ↗
The company is soon to seek regulatory approval in the U.S. and abroad. 
Via Investor's Business Daily
News headline image
Navigating 5 Analyst Ratings For NovoCure ↗
 
Via Benzinga
News headline image
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks. 
Via Benzinga
News headline image
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025? ↗
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates ↗
 
Via Benzinga
Topics Stocks
News headline image
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients ↗
NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. 
Via Benzinga
News headline image
This Gap Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
NovoCure (NVCR) Q3 2024 Earnings Call Transcript ↗
NVCR earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips ↗
U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session. 
Via Benzinga
Topics Stocks
News headline image
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients ↗
NovoCure's Optune Lua, a tumor-treating fields device, gains FDA approval for use with PD-1/PD-L1 inhibitors or docetaxel in metastatic non-small cell lung cancer patients, demonstrating significant... 
Via Benzinga
News headline image
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗
The company could have a long path ahead to reimbursement and, ultimately, sales. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.